Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A phase 3 trial of Paltusotine in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by Crinetics Pharmaceuticals Inc., now recruiting.
Overview
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen is a phase 3 interventional study registered as NCT07087054 by Crinetics Pharmaceuticals Inc., with 141 participants planned, started 2025-11-19 and due to reach its primary completion in 2027-08. Interventions recorded: Paltusotine and Placebo.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Crinetics Pharmaceuticals, Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Shares Crinetics Pharmaceuticals and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialDose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Shares Neuroendocrine tumours and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.